Focal segmental glomerulosclerosis (FSGS) is the most common primary glomerular disorder causing end-stage renal disease. Since the first description of this clinicopathological entity in the early 1930s, various studies have identified numerous underlying pathogenetic mechanisms. Nevertheless, FSGS is still a complex, only partially understood and in its classification sometimes confusing disease. A unifying pathophysiological concept has not been identified and might not even exist. However, research efforts of past decades identified FSGS as a podocytopathy with several podocyte molecules being key players in the development and the course of FSGS. Podocytes are crucially involved in the formation of the glomerular barrier and any assault on their delicate physiological balance and architecture can result in the development of proteinuria. The following review article will introduce most recent examples identifying novel players in the complex pathogenesis of FSGS.
Introduction
The term focal segmental glomerulosclerosis (FSGS) stands for a complex clinicopathological entity, which integrates various clinical presentations as well as different underlying pathophysiological aetiologies [1] [2] [3] [4] [5] . However, FSGS is uniformly characterized by the occurrence of proteinuria and the involvement of the podocyte, a specialized epithelial cell, which is essential for the formation and the integrity of the glomerular barrier. For decades, FSGS was mainly investigated in terms of histological description and these efforts culminated in the classification in five morphological subtypes [6] . From an aetiological and functional standpoint, FSGS can be divided into primary and secondary FSGS. The difference between these two groups has major therapeutic implications, as primary FSGS is usually treated empirically with immunomodulatory agents. This treatment concept is mainly based on the theory that a dysregulated immune system contributes to the pathogenesis of FSGS. However, recent studies also identified off-target effects of established immunomodulatory drugs, such as rituximab and cyclosporine A, that can directly affect and modulate podocyte function [7] [8] [9] .
While primary FSGS subsumes all idiopathic cases of FSGS, the group of secondary FSGS presents a kaleidoscopic array of different diseases, all resulting in different degrees of nephron loss and podocyte damage. The greatest contribution in understanding how the podocyte is particularly affected was done by the identification of causative genes in hereditary forms of nephrotic syndrome. Here we will only briefly review some of the most important genes (see therefore also Figure 1) ; for more details we refer to several published reviews on this topic (e.g. [4] ). All identified causative genes in hereditary FSGS locate to the podocyte, where a broad range of cellular functions and compartments can be affected. It was in 1998 that Karl Tryggvason et al. identified, by positional cloning, the slit diaphragm core component nephrin (NPHS1) as a novel gene, which was found to be mutated in congenital nephrotic syndrome of the Finnish type [10] . Since then more and more mutations in the Nphs1 gene were reported and also linked with late/adult-onset of FSGS [11, 12] . Podocin (NPHS2) was the next identified major player in hereditary FSGS [13] . Podocin physically interacts with nephrin, localizes to the slit diaphragm and is enriched in lipid rafts (cellular compartments of high signalling activity) [14] [15] [16] [17] . The genotype phenotype correlation emphasized the importance of the slit diaphragm as a signalling platform for the podocyte [13, 18, 19] . Another molecule identified to be linked with FSGS was CD2-associated protein [20] (CD2AP). CD2AP is an 80 kDA protein and functions as an adaptor/linker molecule and is critical for stabilizing contacts between T-cells and antigen-presenting cells [21] . By generating constitutive knockout mice, Shaw et al. identified the fundamental role of Cd2ap for the integrity of the podocyte [20, 22] and in the following years mutations in the CD2AP gene could be associated to the occurrence of FSGS [23] . The identification of mutations in CD2AP highlighted once more the essential role of signalling events taking place at the slit diaphragm, since CD2AP also links podocin and nephrin to the phosphoinositide 3-OH kinase [15, 24] . Two further identified genes pinpoint to the exclusive role of the podocyte cytoskeleton in the pathogenesis of FSGS, namely mutations found in alpha-actinin-4 and inverted formin 2. While alpha-actinin-4 serves as an actin cross-linking protein [25] , inverted formin 2 is promoting actin nucleation [26] . Reported gainof-function mutations in the alpha-actinin-4 gene lead to an increased binding to F-actin fibres and finally results in unbalanced assembly properties [27] . Mutations in INF2 on the other hand affects actin nucleation processes and loss of function might be reflected by disorganized actin bundles in podocyte foot processes [26, 28] . Furthermore, the ion channel TRPC6, as a podocyte Ca 2+ influx pathway and upstream regulator of podocyte cytoskeleton, has been identified to cause both genetic [29] [30] [31] and acquired [32] FSGS. Interestingly, not only monogenetic mutations, but also heterozygous oligogenetic mutations of key podocyte molecules can result in FSGS in mice [33] pointing towards the importance of genetic modifiers of glomerular diseases. Indeed, gene association studies led to a breakthrough in identifying genomic modifiers explaining the excessive risk for chronic kidney disease in non-diabetic African Americans [34] . One of these studies revealed that coding sequence variants within the APOL1 gene are responsible for a significant part of observed FSGS risk in African Americans [35] .
In summary, the genes mentioned so far play pivotal roles in podocyte physiology and have shed light on fundamental cellular properties, namely the slit diaphragm and the regulation of the cytoskeleton. The aim of this review is to summarize innovative concepts based on recently published examples of new players in the pathogenesis of secondary FSGS.
New identified players in the pathogenesis of FSGS
Role of Arhgap24 in the regulation of cytoskeletal properties in podocytes. The association of podocyte foot process effacement with proteinuria might represent a switch in podocyte actin networks [36] that are paralleled by changes in podocyte foot process motility [37] . It is assumed that podocytes under physiological conditions might exhibit a rather stationary phenotype, which is mainly controlled by the activity of Rho-A with low activity of Cdc42/Rac1 [38] . Under stress and in pathophysiological situations, this phenotype might be shifted to a more migratory behaviour of podocytes, characterized by an increase in Cdc42/Rac1 activity [38] [39] [40] . Small GTPase in-/activating proteins (so-called GAPs and GEFs) play a decisive role in this kind of ying and yang balance between RhoA and Cdc42/Rac1 [41] . By modulating the GTPase activity of Rho GTPase molecules, the cytoskeletal functions will be fine tuned and regulated [41] . Using a combined approach of podocyte cell culture and genetic studies, Shaw et al. could identify Arhgap24, which is a reported Rac1-inactivating GAP, as a highly podocyte-specific protein. Membrane ruffling, which can be interpreted as a surrogate marker for a migratory podocyte phenotype, is negatively regulated by Arhgap24. Interestingly, the expression of the Arhgap24 transcript significantly increases with podocyte differentiation, suggesting that podocytes shift to a more stationary phenotype, when they become highly differentiated. In contrast, the loss of function mutations of the Arhgap24 gene can be found in FSGS patients indicating the critical importance of Arhgap24 for human glomerular disease. The authors identified an Arhgap24 sequence variation (Q158R), which was only present in the patient cohort. In one pedigree, the mutation could be detected in at least three FSGS-affected family members. The sequence variant is affecting the essential GAP domain of Arhgap24, and when transferred to cell systems, this mutation causes similar phenotypes as knockdown of Arhgap24, indicating that the mutation is indeed affecting Arhgap24 activity.
In summary, this innovative study demonstrates the delicate involvement of Rho-GTPase modulation by GAPs in podocyte homeostasis (see Figure 2) . Compared with the usual suspects (e.g. Nphs2), the frequency of the reported sequence variation in the Arhgap24 gene appears rather minuscule, but nevertheless fundamentally supports the concept of Rho-GTPase regulated podocyte phenotypes and related patho-/physiological conditions [42] .
Myo1e a novel human FSGS gene regulating podocyte motility. Another important study by the PodoNet Consortium identified two mutations in the MYO1E gene, which are linked to a childhood-onset and glucocorticoidresistant form of FSGS [43] . In an approach, using whole-genome linkage analysis, they could discover and sequence these mutations in 52 unrelated patients with FSGS. In further experiments, this group could not only demonstrate that MYO1E is highly enriched in human podocytes, but furthermore discovered that mutations (A159P and Y695X) were linked with decreased motility behaviour of human podocytes and mislocalized expression of the MYO1E protein in vitro [43] . This important study again underlines how sensitive podocytes react to an unbalanced cytoskeletal homeostasis leading to the development of FSGS.
CD2AP is linked to the modulation of proteolytic programmes via cathepsin L. Recent work could demonstrate that the induction of a cytosolic variant of the protease cathepsin L is a key event in the development of proteinuric diseases [9, 37, 44] . While the spectrum of functions for cathepsin L is very broad [45] , quite specific implications for podocyte homeostasis were determined: for instance, it was shown that cathepsin L proteolytically degrades dynamin [44] and synaptopodin [9] causing dysregulated podocyte actin networks, foot process effacement and glomerular disease. In a current report, Reiser et al. used the well-established Cd2ap knockout mouse as a model system [20, 46] for FSGS to study the regulatory programmes of cathepsin L action.
So far, it has already been shown that TGF-beta levels are massively elevated in Cd2ap knockout mice [47] [48] [49] . Further studies revealed that TGF-beta drives the nuclear relocation of dendrin resulting in enhanced TGF-beta-mediated apoptosis of podocytes [50] . By combining transgenic animal models and podocyte cell culture techniques, Reiser et al. could now demonstrate that CD2AP directly regulates the TGF-β1-dependent translocation of dendrin from the slit diaphragm (SD) to the nucleus. Interestingly, nuclear dendrin was identified as a transcription factor to promote expression of cytosolic cathepsin L. As a consequence of elevated TGFβ levels and consecutively increased expression of cathepsin L, the podocyte cytoskeleton is affected by proteolytical degradation of synaptopodin and dynamin (for schematic illustration, see Figure 3 ). However, cathepsin L does not only proteolyse dynamin and synaptopodin, but also CD2AP-thereby promoting a positive feedback loop with a sustained action of cathepsin L and an increased apoptotic susceptibility of podocytes to TGF-β1 [51] . As CD2AP is an integral part of the slit diaphragm, these findings underline once more the unique signalling properties of this specialized cell-cell junction. In summary, under physiological conditions, the SD requires intact CD2AP, which appears to act as a kind of gatekeeper as it anchors transcription factors (e. g. dendrin) to the plasma membrane. Any assault upon CD2AP (e.g. mutations or enzymatic destruction) might affect its stabilizing function and result in the translocation of dendrin to the nucleus subsequently sensitizing podocytes towards injury (see Figure 3) .
Altogether, Reiser et al. provide a novel concept linking the slit diaphragm to the regulation of podocyte proteolytic programmes [51] . Future studies will have to examine the role of this regulatory link for its role in human glomerular diseases. mTOR signalling balances podocyte homeostasis and disease. Mammalian target of rapamycin (mTOR) represents an evolutionarily conserved protein kinase regulating an array of essential cellular processes, including translation, transcription and autophagy. mTOR forms two distinct functional complexes, termed mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2), whereby mTORC1 is sensitive to rapamycin and consists of multiple components including Raptor. Recent genetic studies could now dissect the role of the mTOR complexes in podocyte maintenance and disease [52, 53] . mTORC1 centrally regulates the podocyte growth, hypertrophy and de-differentiation whereby the temporospatial context of mTOR activation appears to define the outcome of mTOR action in podocytes: on the one hand, mTOR is required for podocyte development and podocyte maintenance. On the other hand, in glomerular diseases such as diabetic nephropathy mTOR is persistently hyper-activated and ultimately causes podocyte loss, glomerulosclerosis and disease progression [52, 53] (Figure 4 ). These studies thereby might explain the conflicting results that have been obtained with mTORC1 inhibition in the past by preventing glomerular diseases in many animal models, while also causing significant proteinuria in some patients [54] . In summary, these studies indicate that mTOR is a central regulator of podocyte function and further emphasize that a detailed understanding of context-dependent mTOR function is necessary for directed manipulation of mTOR activity to possibly prevent glomerular diseases.
suPAR as a circulating FSGS factor. A study with potentially outstanding clinical implications is the identification of soluble urokinase receptor (suPAR) as a factor involved in the pathogenesis of FSGS [55] . The basis for this work was the clinical observation that in close to 30% of all transplanted FSGS cases, the disease reoccurs in the transplanted graft [56] . As plasmapheresis or immunadsorption attenuates the course of the disease in many cases, a soluble and circulating factor has been assumed for a long time. Based on their previous work, where they identified the urokinase receptor as an important player in podocyte homeostasis [57] , Reiser et al. hypothesized that the soluble form of uPAR might be an FSGS factor candidate regulating podocyte foot process motility. One striking feature of this study was the confirmation that suPAR is not only elevated in serum of twothirds of FSGS patients, but also correlated with the risk of FSGS recurrence after transplantation. Mechanistically, the authors could show that increased levels of suPAR (or serum of FSGS patients) resulted in beta-3 integrin activation in human podocytes, which was interpreted by the authors as a first step in the pathogenesis of FSGS. Future studies will have to determine whether therapeutic approaches targeting suPAR will change the clinical course of FSGS before and after transplantation.
Role for parietal cells in the pathogenesis of FSGS. Besides the loss of podocytes, progressive sclerosis represents a hallmark of FSGS. Moeller et al. could now demonstrate by elegant genetic tracing studies that parietal epithelial cells (PECs) participate in the formation of sclerotic lesions [58] . Interestingly, the loss of podocytes triggers a focal activation of PECs, which subsequently form cellular adhesions with the capillary tuft. At the site of these adhesions, PECs can migrate onto the capillary tuft, where they contribute to fibrotic lesions. These findings might lead to novel therapeutical applications aiming to prevent the profibrotic dysregulation of PECs.
Conclusion and future perspectives
In the field of glomerular research, focal segmental glomerulosclerosis still appears as a chameleon in terms of its complex and kaleidoscopic pathophysiological mechanisms [1] . Nevertheless, insights from hereditary forms of FSGS have contributed to the currently accepted concept that podocytes are the pacemaker of this disease and diverse aspects of podocyte dysfunction can contribute to the development of FSGS. In this review, we have presented very recently published examples of significant clinical relevance identifying novel molecular mechanisms in the pathogenesis of FSGS. These studies highlight the importance of the fine tuning of the podocyte cytoskeleton, the impact of metabolic signalling pathways and the critical role of systemic soluble factors for podocyte homeostasis. In addition, we have learned that the podocentric view on FSGS over the last decade has to be extended on PECs. Some of these findings might potentially change our future diagnostic and treatment strategies of FSGS. However, there is still a lot to learn in terms of understanding which distinct signals or pathways are integrated by podocytes and PECs. Concurrent development of new high throughput sequencing techniques will further enable us to identify novel FSGS genes and focus on specific targets responsible for the development of FSGS. Combining traditional hypothesis-driven research as well as unbiased screening approaches will further deepen our understanding of the podocyte and will hopefully translate into novel therapeutic approaches within this decade. Fig. 4 . Role of mTOR for podocyte maintenance and disease. Different extracellular stimuli result in altered mTOR activity in the podocyte. While mTOR is responsible for podocyte maintenance under physiological situations, excessive activation of this pathway, in conditions like diabetes, lead to maladaptive responses finally resulting in glomerulosclerosis.
